Indexed publication corpus
36,341Multiple myeloma in the citation title
PubMed literature and NIH-funded projects
The page combines annual PubMed counts, target-linked query counts, a recent citation sample, and NIH RePORTER projects. These are record counts and award amounts, not measures of evidence quality or clinical benefit.
Latest complete year
2,421+10% versus the prior year
NIH funding records
127Disease-title matches across three fiscal years
FY2027 retrieved awards
$0.0MRetrieved title-matched award records
Publication volume
Annual PubMed title matches. The current calendar year is incomplete.
Target-linked PubMed records
Reviewed target and therapy terms in titles or abstracts, 2024–2026.
1Proteasome1610
2BCMA1299
3CD381200
4Cereblon1055
5Glucocorticoid receptor825
6DNA alkylation411
7GPRC5D311
NIH-funded multiple myeloma projects
Title-matched project records for FY2025–FY2027. Amounts are the award values returned per application; the current fiscal year is incomplete.
$0FY 2027
CENTRAL ARKANSAS VETERANS HLTHCARE SYS · 5I01BX006235-03
Characterize Drug Resistance in Multiple Myeloma
FENGHUANG ZHAN
$936,370FY 2026
CYTOAGENTS, INC. · 5R44CA295189-02
CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy
Michael D. Howell
$1,879,425FY 2026
MAYO CLINIC ARIZONA · 2P50CA186781-11
Mayo Clinic Multiple Myeloma SPORE - Renewal 2025
Peter Leif Bergsagel
$399,250FY 2026
MAYO CLINIC ARIZONA · 2P50CA186781-11
Project 4: Overcoming resistance to CART cell therapy in multiple myeloma
Saad J. Kenderian
Browse recent PubMed records
Search the 200 retrieved citations by title, journal, author or mapped therapy. Publication dates can reflect a future journal issue and do not necessarily indicate when a record was added to PubMed.
Feb 15, 2027
Clinica chimica acta; international journal of clinical chemistryPMID 42462872
Association of the triglyceride-glucose index with tumor burden in newly diagnosed multiple myeloma: A retrospective cross-sectional study
Zhang J, Xu D, Luo R, Shu W
Aug 4, 2026
Bioactive materialsPMID 42598038
LDH-mediated autophagic full-chain blockade for Multiple Myeloma treatment by targeting circ_0008255/miR-192-5p/ATG2A axis
Wang Z, Ren H, Wang K, Zhang X
Dec 31, 2026
Hematology (Amsterdam, Netherlands)PMID 42781717
miR-877-5P acts as a tumor suppressor in multiple myeloma by targeting MAPK8: a study on prognostic value and functional mechanism
Bai Z, Luo Q, Zhao S
Dec 31, 2026
OncoimmunologyPMID 42740603
STAT3 inhibition for the induction of immunogenic cell death in multiple myeloma
Kepp O, Kroemer G
Dec 31, 2026
Hematology (Amsterdam, Netherlands)PMID 42685232
Serologic follow-up in patients with multiple myeloma without repeated bone marrow studies: a single-institution experience
Alberto-López LJ, Melchor-Melo OE, Gómez-Cabrera MÁ, Velasco-Padilla JR
Dec 31, 2026
Hematology (Amsterdam, Netherlands)PMID 42679119
Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience
An G, Jin J, Cai Z, Jing H
TalquetamabGPRC5DGPRC5D × CD3
Dec 31, 2026
Hematology (Amsterdam, Netherlands)PMID 41930414
Temporal trends in second primary malignancies among long-term survivors of multiple myeloma across treatment eras: a population-based analysis of the SEER database
Lu L, Lin S, Chen Y, Huang Y
Dec 31, 2026
Hematology (Amsterdam, Netherlands)PMID 41918473
Social determinants of health associated with multiple myeloma incidence and survival among a low-income cohort in the Southeastern U.S
Junkins A, Wen W, Lipworth L, Han X
The literature explorer contains the 200 most recent PubMed records with multiple myeloma or plasma cell myeloma in the citation title. Target-level counts use separate PubMed queries across titles and abstracts for reviewed target and therapy terms during 2024–2026; target counts can overlap and are not measures of evidence quality or clinical benefit. NIH RePORTER records require multiple myeloma in the project title and cover the current and two prior fiscal years.